CDKN2D and Alzheimer disease: Research shows that the accumulation of TauO starts in neurons, and patients with AD have a subset of excitatory neurons that exhibit senescence‐associated features, especially cyclin‐dependent kinase inhibitor 2D (CDKN2D/p19).19